Fox Run Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fox Run Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,468	Closed	-$586K	–	963
2022 Q3	$586K	Buy	9,468 +2,254	+31%	+$157K	0.23%	119
2022 Q2	$575K	Buy	7,214 +3,993	+124%	+$378K	0.29%	94
2022 Q1	$339K	Buy	+3,221	New	+$314K	0.19%	224
2020 Q4	–	Sell	-3,598	Closed	-$279K	–	312
2020 Q3	$279K	Buy	+3,598	New	+$248K	0.7%	51
2019 Q2	–	Sell	-18,449	Closed	-$488K	–	717
2019 Q1	$488K	Buy	+18,449	New	+$437K	0.28%	108
2018 Q4	–	Sell	-24,264	Closed	-$475K	–	849
2018 Q3	$475K	Buy	+24,264	New	+$461K	0.21%	194
2018 Q2	–	Sell	-28,727	Closed	-$408K	–	1029
2018 Q1	$408K	Buy	28,727 +9,527	+50%	+$141K	0.1%	387
2017 Q4	$280K	Buy	19,200 +3,400	+22%	+$47.8K	0.08%	485
2017 Q3	$200K	Sell	15,800 -10,800	-41%	-$137K	0.06%	610
2017 Q2	$316K	Buy	+26,600	New	+$331K	0.11%	388
2017 Q1	–	Sell	-12,000	Closed	-$194K	–	828
2016 Q4	$194K	Buy	+12,000	New	+$218K	0.1%	437

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Fox Run Management's HZNP Position: Q4 2022 in Review

Fox Run Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 9,468 shares — an estimated $586K sold.

Fox Run Management first reported a position in HZNP in Q4 2016 and held it in 11 quarters. The position peaked at $586K in Q3 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Fox Run Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Fox Run Management sold 9,468 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $586K.
Fox Run Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 11 quarters.
Fox Run Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $586K in Q3 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Fox Run Management's 13F filing for Q4 2022, filed 7 Feb 2023.